Hydralazine HCl(Apresoline,Adrolazine,Apresrex)

Molecular Weight (MW)	196.64
Formula	C8H8N4.HCl
CAS No.	304-20-1
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other info	Chemical Name: phthalazin-1-ylhydrazine; hydrochloride InChi Key: ZUXNZUWOTSUBMN-UHFFFAOYSA-N InChi Code: InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H SMILES Code: C1=CC=C2C(=C1)C=NN=C2NN.Cl
Synonyms	Hydralazine Hydrochloride; 1-Hydrazinophthalazine; Adrolazine , Apresrex; Apresoline; Hydralazine chloride; Aiselazine; mono-Hydrochloride, Hydralazine; Nepresol

Molecular Weight (MW)

196.64

Formula

C8H8N4.HCl

CAS No.

304-20-1

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: <1 mg/mL

Water: <1 mg/mL

Ethanol: <1 mg/mL

Other info

Chemical Name: phthalazin-1-ylhydrazine; hydrochloride

InChi Key: ZUXNZUWOTSUBMN-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H

SMILES Code: C1=CC=C2C(=C1)C=NN=C2NN.Cl

Synonyms

Hydralazine Hydrochloride; 1-Hydrazinophthalazine; Adrolazine , Apresrex; Apresoline; Hydralazine chloride; Aiselazine; mono-Hydrochloride, Hydralazine; Nepresol

In Vitro	In vitro activity: Hydralazine impairs up-regulation of RAG-2 gene expression and reduces secondary Ig gene rearrangements. Hydralazine subverts B lymphocyte tolerance to self and contributes to generation of pathogenic autoreactivity by disrupting receptor editing. Hydralazine directly scavenges free acrolein, decreasing intracellular acrolein availability and thereby suppressing macromolecular adduction. Hydralazine inhibits cross-linking if adding 30 min after commencing acrolein exposure but is ineffective if added after a 90-min delay. Hydralazine (0.1-10 mM) inhibits both extracellular and intracellular ROS production by inflammatory macrophages, by a ROS-scavenging mechanism probably affecting superoxide radical (O(2)(-))-generation by xanthine oxidase (XO) and nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NADH/NADPH) oxidase. Hydralazine (0.1-10 mM) significantly reduces NO() generation, and this effect is attributable to an inhibition of NOS-2 gene expression and protein synthesis. Hydralazine also effectively blocks COX-2 gene expression which perfectly correlated with a reduction of protein levels and PGE(2) synthesis.
In Vivo	Hydralazine affords strong, dose-dependent protection against the increases in plasma marker enzymes but not the hepatic glutathione depletion produced by allyl alcohol in mice.
Animal model	Mice
Formulation & Dosage	N/A
References	Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6317-22; J Pharmacol Exp Ther. 2004 Sep;310(3):1003-10.

In Vitro

In vitro activity: Hydralazine impairs up-regulation of RAG-2 gene expression and reduces secondary Ig gene rearrangements. Hydralazine subverts B lymphocyte tolerance to self and contributes to generation of pathogenic autoreactivity by disrupting receptor editing. Hydralazine directly scavenges free acrolein, decreasing intracellular acrolein availability and thereby suppressing macromolecular adduction. Hydralazine inhibits cross-linking if adding 30 min after commencing acrolein exposure but is ineffective if added after a 90-min delay. Hydralazine (0.1-10 mM) inhibits both extracellular and intracellular ROS production by inflammatory macrophages, by a ROS-scavenging mechanism probably affecting superoxide radical (O(2)(*-))-generation by xanthine oxidase (XO) and nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NADH/NADPH) oxidase. Hydralazine (0.1-10 mM) significantly reduces NO(*) generation, and this effect is attributable to an inhibition of NOS-2 gene expression and protein synthesis. Hydralazine also effectively blocks COX-2 gene expression which perfectly correlated with a reduction of protein levels and PGE(2) synthesis.

In Vivo

Hydralazine affords strong, dose-dependent protection against the increases in plasma marker enzymes but not the hepatic glutathione depletion produced by allyl alcohol in mice.

Animal model

Mice

Formulation & Dosage

N/A

References

Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6317-22; J Pharmacol Exp Ther. 2004 Sep;310(3):1003-10.

CAS NO:	304-20-1
规格:	≥98%

包装	价格(元)
250mg	询价
500mg	询价
1g	询价
2g	询价
5g	询价